Used in targeted cancer therapies, particularly for gastrointestinal cancers such as colorectal and gastric tumors. Binds specifically to GPR20, a receptor overexpressed in certain tumor cells, enabling precise delivery of cytotoxic agents when conjugated to drugs. Supports research and development of antibody-drug conjugates (ADCs) by serving as a reference standard for binding affinity, specificity, and functional activity. Facilitates biomarker studies to identify patient populations with GPR20-positive tumors, aiding in personalized medicine approaches. Also utilized in diagnostic assays to detect and quantify GPR20 expression in tissue samples.